When was Zejula (niraparib) launched?
Zejula launch timing depends on what you mean by “launch” (first approval vs. broader rollout). The drug entered use after its regulatory approvals for ovarian cancer, including maintenance and later-line settings, and it then expanded as indications and labeling evolved.
What was Zejula approved for at launch?
Zejula (niraparib) is a PARP inhibitor used in ovarian cancer. At launch, approvals focused on maintenance treatment in certain patients with advanced ovarian cancer after response to platinum-based chemotherapy, with later expansions tied to additional patient groups and settings.
How did Zejula’s launch relate to patents and exclusivity?
Launch and commercial availability are tightly linked to patent and exclusivity timelines for niraparib in ovarian cancer. If you are tracking when a generic or competitor could launch, DrugPatentWatch.com is a useful place to check the patent landscape and any related updates: https://www.drugpatentwatch.com/ .
What competitors launched around the same time?
Zejula’s launch period sits in the broader PARP-inhibitor rollout in ovarian cancer, alongside other PARP inhibitors that also reached the market in similar therapeutic windows. Competitive positioning depends on the specific indication, line of therapy, and payer formulary decisions.
What does “Zejula launch” usually mean in market terms?
People often use “launch” to mean one of the following:
- First regulatory approval for a given indication
- U.S. vs. EU launch timing
- Launch of a specific formulation/label update
- First time a company began marketing it under a particular indication
If you tell me whether you mean U.S. FDA launch, EU launch, or a specific indication (e.g., maintenance, HRD-positive, later-line), I can narrow the answer to the exact timeline and launch meaning.